Montelukast and the risk of major adverse cardiovascular events textendash a Danish population-based case-control study

Research output: Contribution to journalConference abstract in journalResearchpeer-review


Background: The leukotriene pathway has previously been associated with an increased risk of major adverse cardiologic events (MACE), and emerging evidence suggest that montelukast, a leukotriene receptor antagonist, might be associated with a decreased risk of MACE. The aim was to assess the potential association between montelukast use and the risk of MACE.Methods: We conducted a population-based case-control study based on Danish health register data. We included all adults who at some point during 2000-2016 lived on the island of Funen, and who (pop 490,000 in 2016) had a first-time occurrence of MACE (n=79,622). For each case, we age- and sex-matched up to 10 disease-free controls (n=793,549). Using conditional logistic regression, we estimated odds ratios (ORs) for MACE associated with cumulative use of montelukast.Results: In total, 900 cases (1.1 and 5,764 controls (0.7 had ever use of montelukast within the study period. A total of 20,727 (26 of the cases, and 61,657 (7.8 of the controls had a high burden of comorbidity (Charlson Comorbidity Index >=3). Ever use of montelukast was associated with a decreased risk of MACE when adjusting for comorbidity and education level (adjusted [adj]OR 0.79; 95% confidence interval [CI] 0.73-0.85), but no dose-response patterns were observed (cumulative use >=2000 defined daily doses: adjOR 0.65; 95%CI 0.47-0.88; long-term use >=10 years: adjOR 0.44; 95%CI 0.15-1.25). When further adjusting for respiratory- and antihypertensive treatment the decreased risk of MACE remained almost unchanged (adjOR 0.86; 95%CI 0.79-0.93]).Conclusion: We confirmed the previous reported decreased risk of MACE in patients treated with montelukast.FootnotesCite this article as: European Respiratory Journal 2018 52: Suppl. 62, PA4475.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at (ERS member access only).
Original languageEnglish
Article numberPA4475
JournalEuropean Respiratory Journal
Issue numberSuppl. 62
Number of pages1
Publication statusPublished - 2018
EventERS International Congress 2018 - Paris, France
Duration: 15. Sep 201819. Sep 2018


ConferenceERS International Congress 2018


Dive into the research topics of 'Montelukast and the risk of major adverse cardiovascular events textendash a Danish population-based case-control study'. Together they form a unique fingerprint.

Cite this